Login
Companies $PSNL
$14.59 -$0.21 (1.42%) After hours
Personalis, Inc. logo

Personalis, Inc.

personalis.com

What Do They Do?

Provides cancer genomic testing for patients and drug developers, plus sequencing services for diagnostic businesses and population-research programs.

How Do They Make Money?

Customers buy genomic testing services through contracts, statements of work, or purchase orders; payment is due after invoicing.

FY2025 revenue

Who Are Their Customers?

Drug-development and diagnostic organizations, research institutions and government programs, and cancer patients buy its tests. Personalis sells through a small direct sales force and co-commercializes NeXT Personal Dx with Tempus.

Customers above 10% of revenue, FY2025
of revenue from two customers (22%, 17%)
FY2024: 37% from two customers

Do Revenues Turn Into Profits?

No. It lost $81.3M in FY2025.

Operating income, FY2025
−126% of revenue
▼ −29% (Loss) vs FY2024 (−$68.3M, −81%)
Net income, FY2025
−117% of revenue
▲ 0% (Loss) vs FY2024 (−$81.3M, −96%)
Free cash flow, FY2025
−114% of revenue
▼ −70% (Loss) vs FY2024 (−$46.8M, −55%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +77%
vs $14.5M in Q3 FY2025
Net income
▼ −56% (Loss)
vs −$21.7M in Q3 FY2025
  • Jul 20, 2026 Personalis agreed to merge with Tempus The proposed merger would make Personalis a wholly owned Tempus subsidiary, subject to the agreement's terms and conditions.

Shrinking. Revenue fell 19% in 4 years, from $85.5M in FY2021 to $69.6M in FY2025, about 5% a year.

Clinical diagnostics The older report described clinical diagnostics as an area for future expansion after launching new offerings; the latest report details tests ordered for patients, including personalized monitoring and tumor profiling.

Who Do They Compete With?

Competes with Adela, Caris Life Sciences, DELFI Diagnostics, Exact Sciences, Foresight Diagnostics, Foundation Medicine, GRAIL, Guardant Health, Haystack Oncology, Laboratory Corporation of America Holdings, MedGenome, Myriad, Natera, NeoGenomics, Predicine, SAGA Diagnostics, Veracyte, Illumina, and Thermo Fisher Scientific

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support